KRAS and lung cancer: In this research, there were three mutually exclusive triples that independently predicted shorter survival of LUAD patients than the wild‐type samples, namely “TP53 subtype one–KRAS subtype three–FAM47C subtype two,” “KEAP1 subtype two–FAT3 subtype one ‐ EGFR subtype one,” and “TP53 subtype one–MUC16 subtype one–KRAS subtype three.” Although, TP53 mutations,84, 85 KRAS mutations,86, 87 and KEAP1 mutations88 were predictive of survival of lung cancer patients.